-
公开(公告)号：US20130011393A1
公开(公告)日：2013-01-10
申请号：US13519544
申请日：2011-01-12
IPC分类号： C40B30/04 , C40B40/06 , G06F19/24 , A61K39/395
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118
摘要： The invention provides materials and methods for prognosing cancer, and predicting an individual's responsiveness to cancer treatments, methods of treating cancer, and materials and methods for obtaining BAD pathway gene expression profiles useful in carrying out the methods of the invention.
摘要翻译： 本发明提供用于预测癌症的物质和方法，以及预测个体对癌症治疗的反应性，治疗癌症的方法，以及用于获得用于实施本发明方法的BAD途径基因表达谱的材料和方法。
-
公开(公告)号：US20110166095A1
公开(公告)日：2011-07-07
申请号：US12975970
申请日：2010-12-22
IPC分类号： A61K31/7064 , C12Q1/02 , C40B30/06 , A61P35/00
CPC分类号： G01N33/57449 , G01N33/57484 , G01N2800/52
摘要： The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.
摘要翻译： BAD蛋白的磷酸化状态是卵巢癌细胞对铂化疗反应的决定因素。 间接操作BAD磷酸化状态影响顺铂敏感性。 BAD磷酸化代表了预测铂敏感性的生物标志物，并且是增加铂敏感性的治疗靶标。 该方法使用针对特定氨基酸残基或位点的磷酸特异性抗体。 磷酸特异性蛋白质表征方法包括免疫组织化学（IHC），流式细胞术，免疫荧光，捕获和检测或反相测定。
-
公开(公告)号：US09063143B2
公开(公告)日：2015-06-23
申请号：US12975970
申请日：2010-12-22
IPC分类号： G01N33/53 , G01N33/574
CPC分类号： G01N33/57449 , G01N33/57484 , G01N2800/52
摘要： The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.
摘要翻译： BAD蛋白的磷酸化状态是卵巢癌细胞对铂化疗反应的决定因素。 间接操作BAD磷酸化状态影响顺铂敏感性。 BAD磷酸化代表了预测铂敏感性的生物标志物，并且是增加铂敏感性的治疗靶标。 该方法使用针对特定氨基酸残基或位点的磷酸特异性抗体。 磷酸特异性蛋白质表征方法包括免疫组织化学（IHC），流式细胞术，免疫荧光，捕获和检测或反相测定。
-
4.发明授权公开(公告)号：US08741575B2
公开(公告)日：2014-06-03
申请号：US13597753
申请日：2012-08-29
申请人： Domenico Coppola , Dung-Tsa Chen , Steven Brem
发明人： Domenico Coppola , Dung-Tsa Chen , Steven Brem
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： The present invention relates to biomarkers for neoplasias such as high grade gliomas. The inventors have discovered that the overexpression of senescence associated genes (SAG) is associated with a poor prognosis in subjects with high grade gliomas. The present invention provides SAG biomarkers for predicting response to therapy for subjects having high grade glioma based on dividing the samples into high and low risk groups; diagnosing high grade glioma; monitoring progression of high grade glioma from one biological state to another; and determining efficacy of treatment for high grade gliomas.
摘要翻译： 本发明涉及用于肿瘤的生物标志物，例如高级胶质瘤。 本发明人已经发现衰老相关基因（SAG）的过度表达与高级别胶质瘤受试者的预后差相关。 本发明提供了SAG生物标志物，用于基于将样品分为高和低风险组来预测具有高级胶质瘤的受试者的治疗反应; 诊断高级胶质瘤; 监测高级胶质瘤从一种生物状态到另一种生物状态的进展; 并确定治疗高级胶质瘤的疗效。
-
5.发明申请METHODS OF PREDICTING HIGH GRADE GLIOMAS USING SENESCENCE ASSOCIATED GENES 有权使用SENESCENCE相关基因预测高等级GLIOMAS的方法公开(公告)号：US20120322687A1
公开(公告)日：2012-12-20
申请号：US13597753
申请日：2012-08-29
申请人： Domenico Coppola , Dung-Tsa Chen , Steven Brem
发明人： Domenico Coppola , Dung-Tsa Chen , Steven Brem
IPC分类号： C40B30/04 , C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： The present invention relates to biomarkers for neoplasias such as high grade gliomas. The inventors have discovered that the overexpression of senescence associated genes (SAG) is associated with a poor prognosis in subjects with high grade gliomas. The present invention provides SAG biomarkers for predicting response to therapy for subjects having high grade glioma based on dividing the samples into high and low risk groups; diagnosing high grade glioma; monitoring progression of high grade glioma from one biological state to another; and determining efficacy of treatment for high grade gliomas.
摘要翻译： 本发明涉及用于肿瘤的生物标志物，例如高级胶质瘤。 本发明人已经发现衰老相关基因（SAG）的过度表达与高级别胶质瘤受试者的预后差相关。 本发明提供了SAG生物标志物，用于基于将样品分为高和低风险组来预测具有高级胶质瘤的受试者的治疗反应; 诊断高级胶质瘤; 监测高级胶质瘤从一种生物状态到另一种生物状态的进展; 并确定治疗高级胶质瘤的疗效。
-
公开(公告)号：US20110039723A1
公开(公告)日：2011-02-17
申请号：US12812215
申请日：2009-01-12
申请人： Dung-Tsa Chen , Timothy J. Yeatman
发明人： Dung-Tsa Chen , Timothy J. Yeatman
CPC分类号： G06F19/20 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The invention provides for malignancy-risk gene signatures that predict the risk of developing breast cancer, the recurrence of breast cancer, and/or the metastasis of breast cancer. These signatures have numerous clinical applications including assessing risk of breast cancer development following routine breast biopsy, assessing the need for adjuvant radiotherapy after lumpectomy, and determining the need for completion mastectomy following lumpectomy for the breast cancer patient and other treatment plans that are personalized for the patient.
摘要翻译： 本发明提供了预测乳腺癌发展，乳腺癌复发和/或乳腺癌转移的风险的恶性肿瘤风险基因特征。 这些签名具有许多临床应用，包括评估常规乳腺活检后乳腺癌发展的风险，评估在乳房切除术后辅助放疗的需要，以及确定乳腺癌患者乳房切除术后完成乳房切除术的必要性以及其他治疗计划 患者。
-
公开(公告)号：US09195796B2
公开(公告)日：2015-11-24
申请号：US12812215
申请日：2009-01-12
申请人： Dung-Tsa Chen , Timothy J. Yeatman
发明人： Dung-Tsa Chen , Timothy J. Yeatman
CPC分类号： G06F19/20 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The invention provides for malignancy-risk gene signatures that predict the risk of developing breast cancer, the recurrence of breast cancer, and/or the metastasis of breast cancer. These signatures have numerous clinical applications including assessing risk of breast cancer development following routine breast biopsy, assessing the need for adjuvant radiotherapy after lumpectomy, and determining the need for completion mastectomy following lumpectomy for the breast cancer patient and other treatment plans that are personalized for the patient.
摘要翻译： 本发明提供了预测乳腺癌发展，乳腺癌复发和/或乳腺癌转移的风险的恶性肿瘤风险基因特征。 这些签名具有许多临床应用，包括评估常规乳腺活检后乳腺癌发展的风险，评估在乳房切除术后辅助放疗的需要，以及确定乳腺癌患者乳房切除术后完成乳房切除术的必要性以及其他治疗计划 患者。
-
公开(公告)号：US20110046002A1
公开(公告)日：2011-02-24
申请号：US12744027
申请日：2008-11-20
申请人： Timothy Yeatman , Dung-Tsa Chen , Aejaz Nasir
发明人： Timothy Yeatman , Dung-Tsa Chen , Aejaz Nasir
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The invention provides a molecular marker set that can be used for prognosis of breast cancer in a patient using histologically normal tissue. The invention also provides methods for evaluating prognosis of breast cancer in a patient based on a molecular molecular signature.
摘要翻译： 本发明提供了可以用于使用组织学正常组织的患者乳腺癌预后的分子标记物组。 本发明还提供了基于分子分子特征评估患者乳腺癌预后的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.02 秒)
